Drug intelligence / Profile preview

labafenogene marselecobac

Development stage: Phase 2
Lead developer: Synlogic
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Labafenogene marselecobac (SYNB1934) is an orally administered, non-systemically absorbed live biotherapeutic product (LBP) developed by Synlogic for the treatment of phenylketonuria (PKU). It consists of a precision-engineered probiotic bacterial strain (*Escherichia coli* Nissle 1917) designed to consume and metabolize phenylalanine (Phe) within the gastrointestinal tract. By degrading Phe before it can be absorbed into the systemic circulation, the therapy aims to reduce blood Phe levels, which are toxic to the brain in patients with PKU. The drug was granted Orphan Drug and Rare Pediatric Disease designations by the FDA. However, in February 2024, Synlogic announced the termination of the Phase 3 Synpheny-3 study after an internal analysis indicated the trial was unlikely to meet its primary endpoint, leading the company to cease operations.

Other names: lisocabtagene maraleucel-Synlogic-phenylketonuria

Beyond the preview

Go deeper on labafenogene marselecobac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on labafenogene marselecobac.

Explore the full profile